X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Lupin Ltd: Emerging Strong - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Lupin Ltd: Emerging Strong

Dec 18, 2001

Last year, Lupin Chemicals and Lupin Laboratories merged to create a giant entity, Lupin Ltd., with sales turnover in excess of Rs 9 bn. The merger has helped the company in consolidating its leadership position in the anti –TB market. Further, the company is taking strides to become a recognized global player in the Cephalosporin (new generation anti-infectives) and is now considering research as a new thrust area. Lupin Chemicals manufactured Rifampicin while Lupin Laboratories manufactured Ethambutol. Together both these molecules command almost the entire anti-TB market. The consolidation helped the company in becoming a world leader in the anti-TB market, with a market share of more than 40% in the domestic anti-TB market, which is estimated at Rs 3.3 bn. In a segment, which registered, de-growth in last two years, Lupin recorded a double-digit growth in this segment.

A higher incidence of HIV in the developed nations has resulted in significant rise in TB cases worldwide. Further, with global agencies like WHO funding anti-TB drugs, the global market is expected to grow considerably after witnessing a plateau. Lupin plans to enter into US$550 m global anti-TB market and is creating a manufacturing facility at Aurangabad with a capital outlay of Rs 200 m, complying with the US FDA specifications. Lupin aims to achieve more than 50% global market share in the anti-TB segment.

The new thrust area for the company is Cephalosporins. Lupin has just commenced a state of art US FDA approved oral Cephalosporin bulk active plant. Cephalosporin enjoys global sales of US $ 11 bn. Several combinations of Cephalosporins, injectable and orals are going off patent. This provides the company good opportunity to develop competencies and launch these products in the generics market.

Lupin plans to market its Cefotaxime Sodium in the US through its US partner, American Pharmaceutical Partners (APP). Cefotaxime formulations have reported sales of US$ 100 m in the year 2000. Lupin will supply the bulk drug to APP who in turn will formulate and market the product in the US. The company expects to achieve sales of US$ 14 m (Rs 680 m) in the first year of launch. The company has identified four other anti-infective molecules whose patents expire in 2002.

The company is also aggressively launching new products to reduce its therapeutic segment dependence. The company has launched new products in cardiovascular, cephalosporin and herbal segments with plans to launch 40 new products in the current year. Lupin also plans to become a dominant player in the phytochemistry (alternative medicine) segment and has launched a range of products. The company has recently launched 3 herbal products namely: Anxicalm for anxiety, J.Wort for depression and Fibril Rich for the regulation of bowel movement.

Though late, Lupin is now recognizing R&D as a thrust area. The company has established state-of-the-art R&D centre spread over an area of 19 acres at Pune. Lupin has 6 molecules in the pipeline and has plans to file 4 ANDA and 2 INDA in FY02 in the area of neurology, asthma, dermatology, herbal medicines and NDDS (New Drug Delivery System) in Cephalosporins.

The merger has helped Lupin to catapult its position in the league of few Indian pharma companies with Rs 10 bn plus mark. However, company lacks presence in specialty pharma segment and both the company’s key segments (anti-TB and Cephalosporin) are highly price competitive and margins are unlikely to be lucrative. Hence, Lupin would have to push hard to drive growth in the domestic market. In the exports front, though the company is taking the right steps, it seems to be a bit late in cashing on the generic opportunity as it lacks an ANDA pipeline. Even on the exports front, the company would face competition from players from domestic pharma majors.

However, the company seems to be rushing to make up for being a late entrant. To summarize, though the road ahead would not be smooth and easy, the company seems to have right plans in place. At the current market price of Rs 115, the stock trades at 7.6x FY01 earnings.


Equitymaster requests your view! Post a comment on "Lupin Ltd: Emerging Strong". Click here!

  

More Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 24, 2019 (Close)

TRACK LUPIN

LUPIN - DR. REDDYS LAB COMPARISON

COMPARE LUPIN WITH

MARKET STATS